At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 enrolled
Drug / intervention
Valacyclovir +1 moredrug
Likely dose
Valacyclovir 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, 2-Way Crossover, Bioequivalence Study of Valacyclovir 1000 mg Tablet and Valtrex Administered as 1 x 1000 mg Tablet in Healthy Subjects Under Fed Conditions
In Brief
A Phase 1 clinical trial evaluating Valacyclovir for Healthy. Completed, enrolled 36 participants across 1 site.
Detailed Summary
The objective of this study was to compare the rate and extent of absorption of Teva Pharmaceuticals USA valacyclovir and GlaxoSmithKline, USA (Valtrex) valacyclovir, administered as 1 x 1000 mg tablet under fed conditions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
Collaborators--
Timeline
Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2004
Primary CompletionSep 2004
First PostedJun 2010
TodayJul 2026
First PostedJun 23, 2010
Enrollment StartSep 1, 2004
Primary CompletionSep 1, 2004
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 16.0 years ago
Interventions
Valacyclovirdrug
Test 1000 mg Tablet
Valacyclovirdrug
Reference Listed Valacyclovir 1000 mg Tablet